Atrial Fibrillation in a Patient with Hemophilia A: A Case Report and Therapeutic Challenges

Abstract

The increasing age of patients with congenital hemophilia poses new challenges for clinicians. Not only the consequences of bleeding but also age-related diseases, especially cardiovascular disorders, are of great concern. Factors such as hypertension, diabetes, or hyperlipidemia further increase the cardiovascular risk in elderly patients with hemophilia. Preventive treatment of these cardiovascular diseases may therefore also be necessary in hemophilia patients. However, determining the optimal level of anticoagulation in patients with reduced levels of coagulation factors is often difficult and requires an individualized approach. Given the absence of substantial evidence from large clinical trials, clinicians rely on case reports and expert opinions to guide the therapy. This case report details the individual risk–benefit assessment and management of a 57-year-old hemophilia A patient with atrial fibrillation.

Keywords

atrial fibrillation - anticoagulation - therapy - hemophilia A

Data Availability

Data may be requested for academic collaboration from the corresponding author.

Authorship Contributions

K.A., J.S., G.U, S.H., and T.B. were responsible for the treatment of the patient. K.A. collected and analyzed the clinical data. G.U., K.A., and T.B. analyzed the data, interpreted the results, and wrote the manuscript. All authors read and approved the manuscript.

Publikationsverlauf

Eingereicht: 16. September 2024

Angenommen: 03. Dezember 2024

Artikel online veröffentlicht:
06. Mai 2025

• References

• 1 Franchini M, Focosi D, Mannucci PM. How we manage cardiovascular disease in patients with hemophilia. Haematologica 2023; 108 (07) 1748-1757
• 2 Shapiro S, Benson G, Evans G, Harrison C, Mangles S, Makris M. Cardiovascular disease in hereditary haemophilia: the challenges of longevity. Br J Haematol 2022; 197 (04) 397-406
• 3 Kamphuisen PW, ten Cate H. Cardiovascular risk in patients with hemophilia. Blood 2014; 123 (09) 1297-1301
• 4 Lövdahl S, Henriksson KM, Baghaei F, Holmström M, Berntorp E, Astermark J. Hypertension and cardiovascular diseases in Swedish persons with haemophilia - a longitudinal registry study. Thromb Res 2019; 181: 106-111
• 5 Guillet B, Cayla G, Lebreton A. et al. Long-term antithrombotic treatments prescribed for cardiovascular diseases in patients with hemophilia: results from the French Registry. Thromb Haemost 2021; 121 (03) 287-296
• 6 Srivastava A, Santagostino E, Dougall A. et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl. 06) 1-158
• 7 Schutgens REG, Jimenez-Yuste V, Escobar M. et al. Antithrombotic treatment in patients with hemophilia: an EHA-ISTH-EAHAD-ESO clinical practice guidance. HemaSphere 2023; 7 (06) e900
• 8 Schutgens RE, Klamroth R, Pabinger I, Dolan G. ADVANCE working group. Management of atrial fibrillation in people with haemophilia–a consensus view by the ADVANCE Working Group. Haemophilia 2014; 20 (06) e417-e420
• 9 Shapiro AD, Hardesty BM, Peyvandi F, Iorio A. Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: a scoping review. Res Pract Thromb Haemost 2022; 7 (01) 100007
• 10 Aguilar C. Antithrombotic therapy in a patient with mild haemophilia A and atrial fibrillation: case report and brief review of the literature. Blood Coagul Fibrinolysis 2015; 26 (03) 346-349
• 11 Elayi CS, Whitbeck MG, Charnigo R. et al; AFFIRM Study Investigators. Is there an association between external cardioversions and long-term mortality and morbidity? Insights from the Atrial Fibrillation Follow-up Investigation of Rhythm Management study. Circ Arrhythm Electrophysiol 2011; 4 (04) 465-469
• 12 Tilz RR, Potpara T, Chen J. et al. Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey. Europace 2017; 19 (10) 1737-1742
• 13 Airaksinen KEJ. How to optimize cardioversion of atrial fibrillation. J Clin Med 2022; 11 (12) 3372
• 14 Brandes A, Crijns HJGM, Rienstra M. et al. Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure. Europace 2020; 22 (08) 1149-1161
• 15 Uminski K, Xu Y, Zahrai A. et al. Management strategies in persons with inherited haemophilia requiring antithrombotic therapy: a scoping review. Haemophilia 2024; 30 (01) 16-50
• 16 Connell NT, Flood VH, Brignardello-Petersen R. et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021; 5 (01) 301-325
• 17 Fransen van de Putte DE, Fischer K, Makris M. et al. History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia. Eur J Haematol 2012; 89 (04) 336-339
• 18 Klamroth R, Ay C, De Moerloose P. et al. Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - a modified Delphi consensus by the ADVANCE Working Group. Haemophilia 2023; 29 (01) 21-32
• 19 Murray NP, Muñoz L, Minzer S, Lopez MA. Management of thrombosis risk in a carrier of hemophilia A with low factor VIII levels with atrial fibrillation: a clinical case and literature review. Case Rep Hematol 2018; 2018: 2615838
• 20 Benali K, Barré V, Hermida A. et al. Recurrences of atrial fibrillation despite durable pulmonary vein isolation: the PARTY-PVI study. Circ Arrhythm Electrophysiol 2023; 16 (03) e011354
• 21 Sticherling C, Marin F, Birnie D. et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace 2015; 17 (08) 1197-1214
• 22 Biffi M, Boriani G, Bartolotti M, Bacchi Reggiani L, Zannoli R, Branzi A. Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. Heart 2002; 87 (05) 443-448